UN secretary-general offers Lavrov condolences on Churkin’s deathWorld February 21, 19:53
OPEC does not see problems regarding growth of Russian oil exportBusiness & Economy February 21, 19:46
Kremlin to bake 100,000 pancakes for MaslenitsaSociety & Culture February 21, 19:23
Production of Mercedes Benz cars to start in Russia in 2019Business & Economy February 21, 18:43
UN Security Council holds a minute of silence in memory of Russia’s deceased envoyWorld February 21, 18:30
Russia and US might launch joint operations against terrorists in Raqqa — ministerWorld February 21, 18:17
Ankara’s talks with Moscow over purchase of S-400 go on positivelyMilitary & Defense February 21, 18:07
Russia's Autovaz starts Lada Vesta sales in GermanyBusiness & Economy February 21, 17:31
Syrian opposition’s Moscow Group to take part in Geneva talksWorld February 21, 17:21
GENEVA, June 14. /TASS/. The Court of Arbitration for Sport announced on Tuesday that it would announce its decision regarding an appeal from Russian tennis player Maria Sharapova before July 18.
According to various media reports earlier in the day, tennis star Sharapova has filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed last week by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
"In her appeal to the CAS, Ms Sharapova seeks the annulment of the Tribunal’s decision to sanction her with a two-year period of ineligibility further to an anti-doping rule violation," the CAS said in its statement. "Ms Sharapova submits that the period of ineligibility should be eliminated, or in the alternative, reduced."
"The parties have agreed to an expedited procedure which will allow the CAS to render a decision, at the latest, on 18 July 2016," the statement added.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.